208 related articles for article (PubMed ID: 15658847)
21. Overexpression of UDP-glucose dehydrogenase in Escherichia coli results in decreased biosynthesis of K5 polysaccharide.
Roman E; Roberts I; Lidholt K; Kusche-Gullberg M
Biochem J; 2003 Sep; 374(Pt 3):767-72. PubMed ID: 12775214
[TBL] [Abstract][Full Text] [Related]
22. Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin.
Kuberan B; Beeler DL; Lawrence R; Lech M; Rosenberg RD
J Am Chem Soc; 2003 Oct; 125(41):12424-5. PubMed ID: 14531682
[TBL] [Abstract][Full Text] [Related]
23. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans.
Noti C; Seeberger PH
Chem Biol; 2005 Jul; 12(7):731-56. PubMed ID: 16039522
[TBL] [Abstract][Full Text] [Related]
24. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
25. The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin.
Yoon SJ; Yu MA; Pyun YR; Hwang JK; Chu DC; Juneja LR; Mourão PA
Thromb Res; 2003; 112(3):151-8. PubMed ID: 14967412
[TBL] [Abstract][Full Text] [Related]
26. Purified polysaccharides of Geoffroea spinosa barks have anticoagulant and antithrombotic activities devoid of hemorrhagic risks.
Souza RO; Assreuy AM; Madeira JC; Chagas FD; Parreiras LA; Santos GR; Mourão PA; Pereira MG
Carbohydr Polym; 2015 Jun; 124():208-15. PubMed ID: 25839813
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulant activity of native and partially degraded glycoglucuronomannan after chemical sulfation.
de Oliveira Barddal HP; Gracher AH; Simas-Tosin FF; Iacomini M; Cipriani TR
Int J Biol Macromol; 2015 Sep; 80():328-33. PubMed ID: 26136143
[TBL] [Abstract][Full Text] [Related]
28. Biosynthesis of the Escherichia coli K5 capsular polysaccharide.
Griffiths G; Barrett B; Cook N; Roberts IS
Biochem Soc Trans; 1999 Aug; 27(4):507-12. PubMed ID: 10917630
[No Abstract] [Full Text] [Related]
29. Purification of the Escherichia coli K5 capsular polysaccharide and use of high-performance capillary electrophoresis to qualitative and quantitative monitor the process.
Volpi N
Electrophoresis; 2004 Oct; 25(18-19):3307-12. PubMed ID: 15472951
[TBL] [Abstract][Full Text] [Related]
30. Structure of a teichoic acid-like O-polysaccharide of Escherichia coli O29.
Perepelov AV; Wang Q; Senchenkova SN; Shevelev SD; Zhao G; Shashkov AS; Feng L; Knirel YA; Wang L
Carbohydr Res; 2006 Sep; 341(12):2176-80. PubMed ID: 16784735
[TBL] [Abstract][Full Text] [Related]
31. Substrate specificities of glycosyltransferases involved in formation of heparin precursor and E. coli K5 capsular polysaccharides.
Lidholt K; Fjelstad M; Jann K; Lindahl U
Carbohydr Res; 1994 Mar; 255():87-101. PubMed ID: 8181017
[TBL] [Abstract][Full Text] [Related]
32. A novel capsular polysaccharide from Rhizobium rubi strain DSM 30149.
De Castro C; Fregolino E; Gargiulo V; Lanzetta R; Parrilli M
Carbohydr Res; 2008 Jul; 343(9):1482-5. PubMed ID: 18468587
[TBL] [Abstract][Full Text] [Related]
33. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
34. O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
Borgenström M; Wärri A; Hiilesvuo K; Käkönen R; Käkönen S; Nissinen L; Pihlavisto M; Marjamäki A; Vlodavsky I; Naggi A; Torri G; Casu B; Veromaa T; Salmivirta M; Elenius K
Semin Thromb Hemost; 2007 Jul; 33(5):547-56. PubMed ID: 17629853
[TBL] [Abstract][Full Text] [Related]
35. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide.
Berteau O; Mulloy B
Glycobiology; 2003 Jun; 13(6):29R-40R. PubMed ID: 12626402
[TBL] [Abstract][Full Text] [Related]
36. Heparin: from animal organ extract to designer drug.
Middeldorp S
Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
[TBL] [Abstract][Full Text] [Related]
37. Biosynthesis of the Escherichia coli K5 polysaccharide, a representative of group II capsular polysaccharides: polymerization in vitro and characterization of the product.
Finke A; Bronner D; Nikolaev AV; Jann B; Jann K
J Bacteriol; 1991 Jul; 173(13):4088-94. PubMed ID: 1829455
[TBL] [Abstract][Full Text] [Related]
38. The future of anticoagulation.
Hoppensteadt DA; Jeske W; Walenga J; Fareed J
Semin Respir Crit Care Med; 2008 Feb; 29(1):90-9. PubMed ID: 18302091
[TBL] [Abstract][Full Text] [Related]
39. Full NMR assignment and revised structure for the capsular polysaccharide from Streptococcus pneumoniae type 15B.
Jones C; Lemercinier X
Carbohydr Res; 2005 Feb; 340(3):403-9. PubMed ID: 15680595
[TBL] [Abstract][Full Text] [Related]
40. Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents.
Li P; Sheng J; Liu Y; Li J; Liu J; Wang F
Med Res Rev; 2013 May; 33(3):665-92. PubMed ID: 22495734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
